DYNLL1, dynein light chain LC8-type 1, 8655

N. diseases: 103; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE The prostate-specific G-protein coupled receptor (PSGR, or OR51E2) is an olfactory receptor family member with highly specific expression in human prostate epithelium that is highly overexpressed in PIN and prostate cancer. 27280498 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Strong immunostaining for CRISP-3 is common in HG-PIN and preserved in most PCa specimens, which warrant further immunohistochemical studies of CRISP-3 in PCa. 16388501 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE Prolonged treatment of adult rodents with estrogens along with androgens also leads to epithelial metaplasia, PIN-like lesions and even adenocarcinoma of prostate speaking for the role of estrogen in prostate cancer development. 15663993 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE No association was found for correlation of PCA3 score change with age >65 years (p=0.975), family history of prostate cancer (p=0.796), positive DRE (p=0.179), use of 5-alpha-reductase inhibitors (p=0.793) and BPH/prostatitis/HG-PIN/ASAP diagnosis (p=0.428). 25862908 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE The clinical importance of recognizing PIN is based on its strong association with prostatic carcinoma. 8700801 1996
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages. 30012567 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 AlteredExpression disease BEFREE In the present communication, we found increased LIV-1 expression in benign, PIN, primary and bone metastatic human prostate cancer. 22110740 2011
CUI: C3273239
Disease: Proliferative Inflammatory Atrophy
Proliferative Inflammatory Atrophy 		0.020 Biomarker disease BEFREE De Marzo proposed that proliferative inflammatory atrophy (PIA) is a precursor to PIN and cancer. 17935971 2008
CUI: C3273239
Disease: Proliferative Inflammatory Atrophy
Proliferative Inflammatory Atrophy 		0.020 AlteredExpression disease BEFREE Several genes showed overlapping expression patterns between PIA and PIN, and HGPIN and invasive carcinoma. 22025306 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE Utilizing a novel approach for deconvolution, we analyze the transcriptomes of nearly 6750 tissue regions and extract distinct expression profiles for the different tissue components, such as stroma, normal and PIN glands, immune cells and cancer. 29925878 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE De Marzo proposed that proliferative inflammatory atrophy (PIA) is a precursor to PIN and cancer. 17935971 2008
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 GeneticVariation group BEFREE We illustrate our approach through the detailed biochemical and structural characterization of a previously unknown cancer-associated mutation (G79C) affecting the 8 kDa dynein light chain (DNCL1). 15897869 2005
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 AlteredExpression group BEFREE Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis. 26514520 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE Although the most frequent benign mimickers that prevent a definitive diagnosis of cancer in needle biopsies are the small size of the atypical foci, PIN and partial atrophy, in TURPs, they are adenosis and cautery artifact. 27299192 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 Biomarker group BEFREE PIN is associated with progressive abnormalities of phenotype and genotype intermediate between normal prostatic epithelium and cancer, indicating impairment of cell differentiation and regulatory control with advancing stages of prostatic carcinogenesis. 8700801 1996
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 AlteredExpression group BEFREE Deleted in liver cancer-1(DLC-1) gene expression is frequently down-regulated or deleted in many types of human cancer. 20882354 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 AlteredExpression group BEFREE DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. 22799310 2012
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.090 GeneticVariation group BEFREE Since inactivation of tumor suppressor genes in cancer cells is also commonly associated with point mutation, we evaluated the incidence of mutation of the DLC-1 gene by PCR-SSCP in 17 primary HCC and 18 HCC cell lines. 12792785 2003
CUI: C0152427
Disease: Polydactyly
Polydactyly 		0.010 Biomarker disease BEFREE Interestingly, phenotypes of Dynll1-deficient mice are very similar to entirely cilia-deficient Kif3a/Ift88-null mice, except that they never present with polydactyly and retain relatively higher signaling outputs in parts of the hedgehog pathway. 31009951 2019
CUI: C4282128
Disease: PATENT DUCTUS ARTERIOSUS 1
PATENT DUCTUS ARTERIOSUS 1 		0.010 PosttranslationalModification disease BEFREE The rate of DLC-1 promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (p < 0.001). 23681804 2013
CUI: C0013274
Disease: Patent ductus arteriosus
Patent ductus arteriosus 		0.010 PosttranslationalModification disease BEFREE The rate of DLC-1 promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (p < 0.001). 23681804 2013
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.010 Biomarker disease BEFREE DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. 23681804 2013
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.010 AlteredExpression disease BEFREE Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model. 31612067 2019
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 PosttranslationalModification disease BEFREE It was further evidenced by an aberrant DLC-1 promoter methylation pattern, which was detected by Southern blotting in 73% (8/11) of NSCLC cell lines with downregulation of the gene. 14661059 2004
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 AlteredExpression disease BEFREE DLC-1 protein expression was absent in six of nine NSCLC cell lines. 17932950 2008